CRISPR Therapeutics AG or Catalyst Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?

Managing SG&A Costs: A Tale of Two Biotechs

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for sustaining growth and profitability. CRISPR Therapeutics AG and Catalyst Pharmaceuticals, Inc. have been navigating this financial landscape since 2014. Over the years, CRISPR Therapeutics AG has seen a steady increase in SG&A expenses, peaking in 2021 with a 1,700% rise from 2014. However, 2023 marked a significant reduction, dropping by 26% from the previous year. In contrast, Catalyst Pharmaceuticals, Inc. maintained a more conservative approach until 2019, after which their SG&A expenses surged, culminating in a 200% increase by 2023. This divergence highlights the strategic differences in cost management between the two companies. As the biotech industry evolves, these financial strategies will play a pivotal role in determining long-term success.